Granulocyte colony-stimulating factor in acute myeloid leukemia

Stem Cells
K UsukiA Urabe

Abstract

The clinical application of recombinant human G-CSF in patients with acute myeloid leukemia (AML) has been controversial because it stimulates the in vitro proliferation of leukemic cells. In order to explore the possibility of predicting in vivo leukemic proliferation after G-CSF administration to AML patients by using in vitro assays, we investigated the leukemic blasts of 30 AML patients, including 14 patients who received G-CSF for severe infection associated with neutropenia following chemotherapy (G-CSF group) and 16 patients who did not (control group). Of the 14 patients in the G-CSF group, 9 showed an increase of leukemic blasts in the peripheral blood during G-CSF administration, while 11 of the 16 control patients developed leukemic resurgence. In the G-CSF group, the frequency of leukemic resurgence among patients whose blasts showed dose-dependent proliferation after addition of G-CSF to cultures was similar to that among patients whose blasts did not. In addition, there were no significant differences between the G-CSF and control groups in [3H]thymidine incorporation by leukemic cells and leukemic colony formation after the addition of G-CSF to cultures. The G-CSF receptor affinity of leukemic blasts was signific...Continue Reading

References

Jan 1, 1977·Journal of Immunological Methods·M W BurgettJ F Monthony
Mar 1, 1992·Blood Reviews·K A Foon, R P Gale
Jul 1, 1991·British Journal of Haematology·J M BennettC Sultan
Dec 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K M TaylorL M Souza
May 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A ThompsonA Fefer
Oct 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G MorstynK Alton
Aug 20, 1987·The New England Journal of Medicine·P J FialkowR Veith
Jun 1, 1982·British Journal of Haematology·J M BennettC Sultan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.